Article
Perilymphatic injections of recombinant interleukin-2 (rIL-2) partially correct the immunologic defects in patients with advanced head and neck squamous cell carcinoma.
The Laryngoscope - 1 May 1992
Melioli G, Margarino G, Scala M, Mereu P, Bertoglio S, Schenone G, Barbaresi M, Machí A M, Santi L, Badellino F
Abstract excerpt
Patients with advanced head and neck squamous cell carcinoma (HNSCC) are severely immunocompromised. In virtually all such patients who have been studied, reduced numbers of circulating CD3+ T-cell-receptor (TCR)alpha/beta+ T lymphocytes, a reduction of natural killer (NK) activity, and a poor in...
Topics
- Aged
- Aged, 80 and over
- Antigens, Surface
- Carcinoma, Squamous Cell
- Female
- Head and Neck Neoplasms
- Humans
- Immunocompromised Host
- Injections, Intralymphatic
- Interleukin-2
- Killer Cells, Lymphokine-Activated